Biologics drive both revenue and risk
Many rheumatology practices run infusion suites for biologic drugs used in rheumatoid arthritis, lupus, vasculitis and other inflammatory diseases. These drugs are expensive, need prior authorization and renewal, and are often subject to step therapy and site-of-care rules. Office visits add complex medical decision-making for drugs that require monitoring, plus joint injections and aspirations.
Infusions and administration codes
| Situation | Administration codes |
|---|---|
| Many monoclonal antibodies and other complex biologic agents | 96413 first hour, 96415 each additional hour (chemotherapy and complex drug administration codes) |
| Other therapeutic infusions | 96365 first hour, 96366 additional hour, 96367 sequential |
| Subcutaneous or intramuscular injection in the office | 96372 (therapeutic) or 96401 (complex drug), as CPT guidance and payer policy direct |
Which administration family applies depends on the drug, CPT guidance and the payer’s policy, so the mapping is set per drug and per payer. Start and stop times for each infusion determine additional-hour codes.
Drug billing and approvals
- Units and wastage: drugs are billed by HCPCS code and units, with modifier JW for discarded drug or JZ when none was discarded from single-dose vials (Medicare), and NDC where required.
- Biosimilars: payers increasingly prefer or require a specific biosimilar, which has its own HCPCS code.
- Step therapy: plans often require trials of preferred drugs first; requests document earlier treatments, responses and reasons for stopping.
- Site of care: some commercial plans pay infusions only in lower-cost settings, or supply the drug through a specialty pharmacy instead of buy-and-bill.
Joint injections and monitoring visits
Arthrocentesis and joint injections are coded by joint size (20600–20611); the codes with ultrasound guidance include it, so guidance is not billed separately. The drug injected is billed on its own line. Office visits for patients on drugs that require intensive monitoring for toxicity often support higher levels of medical decision-making when the monitoring is documented. Approval renewals are tracked before they lapse so infusions are not delayed — see prior authorization services.